Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 5/20 | 0.53 |
| ▸ | GSK3B | P49841 | 3/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | IP6K1 | Q92551 | 10/20 | 0.45 |
| ▸ | IP6K3 | Q96PC2 | 4/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | TEK | Q02763 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4865960 | 0.88 | PIK3CD (0.55) | AKT2GSK3BPIK3CDPIK3CAPIK3CB | |
| SCHEMBL4869946 | 0.84 | PIK3CD (0.55) | AKT2GSK3BPIK3CDPIK3CAPIK3CB | |
| SCHEMBL4875291 | 0.81 | PIK3CD (0.58) | AKT2GSK3BPIK3CDPIK3CAPIK3CB | |
| SCHEMBL14003524 | 0.78 | PIK3CD (0.55) | AKT2GSK3BPIK3CDPIK3CAPIK3CB | |
| SCHEMBL4876064 | 0.76 | AKT2 (0.44) | AKT2GSK3BALDH1A1 | |
| SCHEMBL4879519 | 0.73 | PIK3CD (0.56) | AKT2GSK3BPIK3CDPIK3CAPIK3CB | |
| SCHEMBL30169542 | 0.71 | PIK3CD (0.73) | PIK3CDPIK3CAPIK3CBALDH1A1IP6K1 | |
| SCHEMBL4878824 | 0.71 | PIK3CD (0.73) | PIK3CDPIK3CAPIK3CBALDH1A1IP6K1 | |
| SCHEMBL1001970 | 0.71 | AKT2 (0.74) | AKT2GSK3BCYP2D6CYP2C9RPS6KB1 | |
| SCHEMBL4877211 | 0.71 | AKT2 (0.44) | AKT2GSK3BCYP2D6CYP2C9RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | claimed |
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| EP-1814552-A2 | COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS | Astex Therapeutics Limited (GB) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006051290-A2 | COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | CNKSR1, PRKCH, PRKAR2B | AKT2 412/4885GSK3B 850/4885PIK3CD 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.